Compared to patients who received no oral anticoagulant treatment at hospital discharge, patients with ischemic stroke and atrial fibrillation who received warfarin had a lower risk of major adverse cardiovascular events and spent less time receiving follow-up care at the hospital.
Much of the hesitancy about using the novel oral anticoagulants is the lack of reversal agents for them, but that could change relatively soon. The panelists share information about several investigational anticoagulation reversal agents and their place in real-world practice.
A relatively simple algorithm for stopping and potentially reversing the effects of anticoagulant therapy can be used regardless of which anticoagulant the patient is using. Here, the panelists discuss how to simplify the problem of reversing the effects of anticoagulant therapy.
Vampires may be on to something.
Researchers at the Stanford University School of Medicine’s neurology and neurological sciences department and the Center for Tissue Regeneration, Repair and Restoration at Veterans Affairs Pala Alto Healthcare System report “surprising regenerative activity in young blood.”